Zika Virus Therapeutics Global Market Report 2025

The zika virus therapeutics market size has grown strongly in recent years. It will grow from $30.22 billion in 2024 to $32.16 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth during the historic period can be attributed to the high incidence rate of infection, the disease burden of Zika virus and its associated comorbidities, the increasing demand for preventive measures, the rising significance of public health campaigns, and the expansion of global health initiatives.

The zika virus therapeutics market size is expected to see strong growth in the next few years. It will grow to $40.64 billion in 2029 at a compound annual growth rate (CAGR) of 6%. The growth during the forecast period can be attributed to the rising adoption of clinical trials, increasing demand for therapeutics in Zika-endemic regions, greater investment in R&D, the availability of serology kits for qualitative diagnosis, and the expansion of alternative programs. Key trends in the forecast period include technological advancements in antiviral drug development, the development of serological testing, innovations in monoclonal antibody technology, the emergence of novel therapies, and progress in rapid diagnostic technologies.

The increasing infection rates are expected to drive the expansion of the Zika virus therapeutics market. Infection rates refer to the likelihood of disease transmission within a population over a specific period. The rising incidence of Zika infections is driven by inadequate vector control, environmental conditions that promote mosquito breeding, and limited access to preventive healthcare in affected regions. This surge in infections creates a demand for effective Zika virus therapeutics, prompting investment in vaccines and treatments to mitigate the growing public health threat. For example, in December 2024, the UK Health Security Agency, a UK-based government organization, reported that between January and June 2024, there were eight confirmed cases of the Zika virus, a 700% increase compared to the same period in 2023. As a result, the rising infection rate is expected to propel the Zika virus therapeutics market.

Leading companies in the Zika virus therapeutics market are advancing innovative vaccine technologies, such as second-generation adjuvanted inactivated vaccines, to improve immune responses, enhance efficacy, and provide longer-lasting protection. Second-generation adjuvanted inactivated vaccines combine an inactivated virus with an immune-boosting adjuvant to strengthen the body’s immune defense against infections. For instance, in March 2024, Valneva SE, a France-based biotechnology company specializing in vaccine production, initiated Phase 1 clinical trials for VLA1601. This highly purified inactivated vaccine candidate targets the Zika virus (ZIKV) and is developed using the same manufacturing platform as Valneva's licensed Japanese encephalitis vaccine, IXIARO. The vaccine is formulated with adjuvants to enhance immune response, which is critical for its effectiveness.

In September 2024, Indian Immunologicals, an India-based vaccine manufacturer, partnered with the Indian Council of Medical Research to develop a cost-effective Zika virus vaccine. This collaboration highlights the importance of creating affordable and accessible vaccines for emerging viral diseases, particularly Zika, which poses significant risks to pregnant women. The Indian Council of Medical Research is India’s apex body for biomedical research, focusing on developing safe and effective vaccines to combat public health threats.

Major players in the zika virus therapeutics market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Moderna Inc., DiaSorin S.p.A., Emergent BioSolutions Inc., ARUP Laboratories, Valneva SE, Bharat Biotech International Limited, Euroimmun AG, Tiangen Biotech Co. Ltd., Creative Diagnostics, Inovio Pharmaceuticals Inc., GeoVax Labs Inc., Moleculin Biotech Inc., BioVaxys Technology Corp., Kimer Med Limited, LumiQuick Diagnostics Inc.

North America was the largest region in the zika virus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in zika virus therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the zika virus therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Zika virus therapeutics refer to medical treatments, drugs, or therapies designed to prevent or manage Zika virus infection, which is primarily transmitted through mosquito bites and can cause symptoms such as fever, rash, and joint pain. Treatment for Zika virus is mainly supportive, focusing on symptom relief, hydration, and monitoring for severe complications, including congenital Zika syndrome in newborns.

The primary product types for Zika virus therapeutics include acetaminophen and other non-steroidal anti-inflammatory drugs (NSAIDs). Acetaminophen is a commonly used pain reliever and fever reducer for managing mild to moderate pain and fever. These therapeutics are classified based on vaccine type, including inactivated vaccines, subunit vaccines, live-attenuated vaccines, and other vaccine types. They are administered in various healthcare settings, such as hospitals, clinics, and other medical facilities.

The zika virus therapeutics market research report is one of a series of new reports that provides zika virus therapeutics market statistics, including the zika virus therapeutics industry global market size, regional shares, competitors with the zika virus therapeutics market share, detailed zika virus therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the zika virus therapeutics industry. This zika virus therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The zika virus therapeutics market consists of sales of vaccines, antiviral drugs and antibody based therapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.